Two experienced drug developers, Josh Bilenker and Jeff Engelman, have been working in secret for years on a new biotech company called Treeline Biosciences. This week, they revealed their first cancer-fighting drugs entering human trials and announced $200 million in new funding to support these studies. Since 2021, Treeline has raised a total of $1.1 billion from top investors, giving them the resources to explore multiple treatment approaches. Their first three cancer programs include a drug that breaks down a protein lymphoma cells use to survive, another that targets common mutations in solid tumors (like lung, colon, and pancreatic cancers), and a third that affects a gene linked to T cell lymphomas. Unlike many companies that focus on one drug at a time, Treeline is testing multiple ideas, even if some don’t work out. They plan to share early trial results next year and advance more experimental drugs soon after. The company is also developing targeted antibody treatments that deliver cancer-fighting molecules more precisely. Bilenker and Engelman have decades of experience in cancer drug research, including successful treatments now approved by the FDA. Treeline operates labs in Massachusetts, California, and Switzerland.